4//SEC Filing
Bolzon Bradley J PhD 4
Accession 0000899243-21-026800
CIK 0001674416other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 6:38 PM ET
Size
31.7 KB
Accession
0000899243-21-026800
Insider Transaction Report
Form 4
Bolzon Bradley J PhD
Director
Transactions
- Sale
Common Shares
2021-06-28$151.49/sh−3,144$476,300→ 164,109 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$152.38/sh−3,139$478,309→ 7,617 total - Sale
Common Shares
2021-06-28$154.57/sh−2,281$352,564→ 817 total - Sale
Common Shares
2021-06-28$155.27/sh−132$20,496→ 159,100 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$152.38/sh−1,540$234,660→ 162,569 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$151.49/sh−6,403$970,022→ 10,756 total - Sale
Common Shares
2021-06-28$153.54/sh−2,218$340,549→ 160,351 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$150.65/sh−3,216$484,491→ 17,159 total - Sale
Common Shares
2021-06-28$150.65/sh−1,578$237,726→ 167,253 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$153.54/sh−4,519$693,842→ 3,098 total - Sale
Common Shares
2021-06-28$155.27/sh−268$41,613→ 549 total - Sale
Common Shares
2021-06-28$156.54/sh−269$42,110→ 158,831 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$154.57/sh−1,119$172,959→ 159,232 total(indirect: See Footnote) - Sale
Common Shares
2021-06-28$156.54/sh−549$85,941→ 0 total
Footnotes (10)
- [F1]The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F10]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.
- [F4]These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
- [F5]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
- [F6]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
- [F7]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
- [F8]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
- [F9]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001354345
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 6:38 PM ET
- Size
- 31.7 KB